We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The effects of curcumin on hepatic T2*MRI and liver enzymes in patients with β-thalassemia major: a double-blind randomized controlled clinical trial.
- Authors
Eghbali, Aziz; Nourigheimasi, Shima; Ghasemi, Ali; Afzal, Roghayeh Rahimi; Ashayeri, Neda; Eghbali, Aygin; Khanzadeh, Shokoufeh; Ghaffari, Kazem
- Abstract
Background: Curcumin present in turmeric has been considered due to its cancer-preventive features, antioxidant and anti-inflammatory properties. This double-blind, randomized, controlled clinical trial with a reasonable sample size and longer intervention period was conducted to investigate how oral curcumin affected cardiac and hepatic T2*MRI and liver enzymes in patients with β-thalassemia major. Method: This clinical trial study was conducted on 171 patients over 5 years old. The subjects were randomly divided into a curcumin-treatment group and a placebo group to receive either curcumin capsules twice daily or placebo for 6 months. Patients were examined once a month for 6 months to receive capsules and measure the levels of alanine aminotransferase (ALT), aspartate transferase (AST), alkaline phosphatase (ALP), direct and total bilirubin, ferritin and cardiac and hepatic T2*MRI. Result: There was a significant decrease in levels of AST, ALT, ALP, and bilirubin (direct and total) in the curcumin group compared with the placebo group by the end of the study (p < 0.05). The levels of serum ferritin remained unchanged in both groups at the end of the follow-up period (p > 0.05). No significant differences were observed between the curcumin and placebo groups at baseline values or at the end of the study of cardiac and hepatic T2*MRI and serum magnesium. Conclusion: Administration of curcumin has some beneficial effects on liver function by reducing liver enzymes in patients with beta-thalassemia major.
- Subjects
LIVER enzymes; FERRITIN; ALKALINE phosphatase; RANDOMIZED controlled trials; CLINICAL trials; CURCUMIN; ALANINE aminotransferase
- Publication
Frontiers in Pharmacology, 2023, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2023.1284326